You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康哲藥業(00867.HK)擬收購一家皮膚線專業公司,切入醫美護膚領域
格隆匯 02-01 22:24

格隆匯 2 月 1日丨康哲藥業(00867.HK)宣佈,於2021年2月1日,集團通過公司全資附屬公司向若干第三方賣方("賣方")收購一家皮膚線專業公司Luqa Ventures Co., Limited("目標公司")的全部已發行股份。收購事項完成後,目標公司成為公司的全資附屬公司,其業績及資產與負債將合併入集團的賬目內。

據悉,目標公司皮膚線覆蓋處方藥、醫療器械及醫學美容("醫美")護膚系列產品,種類豐富,可滿足消費者多樣化需求,為市場提供兼顧安全性與療效性的皮膚狀況解決方案。

公吿稱,集團深耕皮膚治療領域,擁有已上市產品及短中長期創新產品儲備,包括國內已上市的喜療妥(多磺酸黏多糖乳膏)、蘭美抒(鹽酸特比萘芬片)以及處於國內註冊性臨牀階段的海外已上市創新生物治療產品替拉珠單抗注射液(Tildrakizumab)等皮膚線產品,已建立一定品牌認知度。集團認為皮膚治療及高端醫美市場前景廣闊,為擴大市場地位,集團其中一項發展策略為通過投資多元化豐富產品矩陣並擴張相關領域版圖。

目標公司產品將與集團現有皮膚線產品產生協同效應互為助力,併為集團填補醫美護膚專業產品線,為集團介入醫美護膚領域帶來重大發展機會。集團將形成覆蓋處方藥、醫療器械及醫美護膚產品的完整皮膚線產品矩陣,實現在皮膚治療領域的縱深發展。同時,集團將利用在中國市場的商業化優勢、經驗豐富的專業人員隊伍和專業高效的學術推廣體系,充分整合醫院、專業醫療機構、互聯網及零售渠道資源,令皮膚產品進一步滲透中國市場,擴大產品和品牌的市場認知度。未來,集團將持續引進全球優質產品,推動皮膚線創新性研究,探索投資機遇,發展打造具有一流競爭力的中國領先皮膚治療及高端醫美線,構築未來新的發展空間,滿足中國消費者日益多樣化的健康與美的需求。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account